Publicación de epiliquid

According to scientists at the Netherlands Cancer institute, a new innovative stool test could be a major step forward in the fight against colorectal cancer. This approach, detailed in a study published by The Lancet Oncology, utilizes cutting-edge DNA analysis techniques to improve early detection rates of the disease. The essence of this new test lies in its ability to detect specific DNA markers associated with colorectal cancer directly from stool samples. This method represents a highly sensitive and entirely non-invasive strategy for identifying the cancer at an early stage, significantly enhancing the likelihood of effective treatment and increasing survival rates. Key Benefits of the New Stool Test: - Accessibility: By being non-invasive, the test could increase screening participation, potentially preventing colorectal cancer-related deaths. - Early Detection: It facilitates the identification of colorectal cancer at its early stages, paving the way for more prompt and efficacious treatment options. - Customized Treatment Plans: The test enables healthcare providers to design treatment strategies that are precisely tailored to the patient’s specific risk factors and early disease indicators. Swissmed Health offers innovative diagnostics and treatments in a number of key areas, including cancer. Please contact us for our comprehensive report on cancer. You can learn more about this study and its importance at: https://lnkd.in/eyKWinkv 📞+357 25010200 #swissmedicalclinics #swissmedical #medical #swissmedicine #medicine #longevity #goodhealth #healthylifestyle #wellness #health #healthconditions #treatment 

El 12th APBCS, hacia nuevas alturas en la atención al cáncer de mama Hoy da comienzo en Bali (Indonesia) la 12th Asia-Pacific Breast Cancer Summit (#APBCS), un evento de primer nivel sobre #cancerdemama, bien consolidado en la región de Asia y El Pacífico. Esta nueva edición, con el lema “Reaching New Heights in Breast Cancer Care”, ha reunido, como en las anteriores, a los mejores expertos en investigaciones globales, regionales y locales para mejorar la atención al paciente con esta enfermedad. El Dr. Javier Cortés Castán, director del IBCC - International Breast Cancer Center (PANGAEA ONCOLOGY, forma parte de este selecto grupo de líderes de opinión claves y estelares, de todo el mundo, invitados a compartir sus conocimientos en cáncer de mama, en distintas sesiones del evento. Mañana, el Dr. Cortés pronunciará una ponencia sobre el cáncer de mama HER2+, subtipo de la enfermedad en el que es autoridad mundial, y, posteriormente, participará en un panel de expertos sobre este subtipo. A continuación, ofrecemos los detalles de la participación del Dr. Javier Cortés: Save the date: 🔎2 de marzo / Convenciones Nusa Dua, en Bali (Indonesia) 📝Session 1: The Evolving Landscape of HER2 Positive Disease 1️⃣ 9:00-9:20h. (Asia/Pacific time) – (2:00 h. CET) 🎤Rol Dr. Javier Cortés: speaker Talk: “Does One Size Fit all for Neoadjuvant / Adjuvant Therapy in HER2+ Breast Cancer” 2️⃣ 9:50-10:30h. (Asia/Pacific time) – (2:50 h. CET) 🎤Rol Dr. Javier Cortés: panel de expertos Board tumor 1: Challenging Cases in HER2 Positive Disease #Oncology #BreastCancer #HER2 #research #InvestigaciónMédica #clinicaltrials #ensayosclinicos

🌍 World Cancer Awareness Day: Understanding the Importance of 𝗧𝘂𝗺𝗼𝗿 𝗕𝗼𝗮𝗿𝗱.🌍 On this Cancer Awareness Day, let's shed light on a critical part of cancer treatment that often goes unnoticed in rural settings: the 𝗧𝘂𝗺𝗼𝗿 𝗕𝗼𝗮𝗿𝗱. A tumor board is a collaborative team of oncologists, radiologists, pathologists, surgeons, and other healthcare specialists who meet to discuss complex cancer cases. The goal is to design personalized treatment plans that offer the best outcomes for patients. Each board member contributes their expertise to recommend a comprehensive, multi-faceted approach, giving patients access to a higher standard of care. At BigOHealth, we believe in raising awareness and advocating for access to advanced, multi-disciplinary care, even in rural settings. That’s why we’re committed to facilitating connections with super-specialists and providing resources to educate patients and families about their options. If you or a loved one is facing a cancer diagnosis, ask about a tumor board in local or reach out to BigOHealth for tumor board. It’s a powerful step toward ensuring the best care and support throughout the journey. Understand the importance of Tumor board from three top oncologist Dr Swarupa Mitra Dr Ankur Bahl Vedant Kabra from Fortis Hospital, Gurgaon. Yashpal Singh Rawat Gaurav R #CancerAwareness #WorldCancerDay #TumorBoard #Oncology #BigOHealth #Healthcare

Que es una evaluación de riesgo de cáncer de mama? En USA, por ejemplo, 1 de cada 8 mujeres desarrollará Cáncer de Mamá durante su vida. Conoces la última tecnología presente para Tratamiento de Cáncer de Mama? Tu cobertura médica o seguro médico tu lo ofrece? En un 100% de los gastos? Estás preparada para ser ese 1 de 8? #LaInformacionEsPoder #BestDoctorsInsurance

🎗️Briota Technologies introduces BreastPro Scan, a revolutionary device for early breast tumor detection! 🎗️ At Briota Technologies, we are dedicated to empowering women's health through innovation. That's why we're happy to introduce BreastPro Scan, a game-changing device designed to revolutionize breast cancer screening. BreastPro Scan utilizes advanced sensors to accurately assess and identify tissue elasticity differences between hard and stiff breast tumors versus normal breast tissue. This means quicker, easier, and more accurate screenings, ultimately leading to earlier detection and improved outcomes. But our technology is only part of the equation. The real heroes in the fight against breast cancer are the women who prioritize their health by attending annual check-ups and performing monthly self-examinations. We salute you for your courage, strength, and commitment to your well-being. Early detection is crucial in defeating cancer, and BreastPro Scan is here to help. Don't wait until it's too late. Schedule your screenings and routine check-ups today. Together, we can #BeatNCDs and #BeatCancer. Join us in spreading awareness and empowering women to take control of their health. Together, we can make a difference. #BreastCancerAwareness #HealthTech #Innovation #WomenEmpowerment #EarlyDetection #FightAgainstCancer #EmpoweringHealthcare Let's change the narrative surrounding breast cancer from fear to empowerment. Together, we can save lives. 💪🎗️ Aditi Samudra Pais Parnita G. Rajashree Shinde Rohini Patil Women Who Code |Breast Cancer Canada |Breast Cancer Trials |Breast Cancer Network Australia |Breast Cancer Awareness Month

According to World Health Organization, around 10 million people die annually from cancer. To prevent this situation from worsening, measures need to be quickly adopted across the world. Therefore, since 2000, the Union for International Cancer Control (UICC) promotes an annual campaign to raise awareness about prevention and the urgent need to seek new solutions on this front. As a CRO with large expertise in oncology, we actively contribute to this search: 15% of our studies focus on this therapeutic area, the most researched by us. Across LATAM, where we have a strategic presence, there are more than 1,500 active trials. Cancer has a greater chance of reversing if diagnosed early. Prevent yourself! - Segundo a OMS, cerca de 10 milhões de pessoas morrem anualmente vítimas de câncer. Para que este quadro não se agrave, medidas precisam ser rapidamente adotadas em todo o mundo. Por isso, a União Internacional para Controle do Câncer (UICC) promove, desde 2000, uma campanha anual para conscientizar sobre a prevenção e a urgente necessidade de buscarmos novas soluções nesta frente. Como CRO com vasta expertise em oncologia, contribuímos ativamente com essa busca: 15% de nossos estudos são focados nesta área terapêutica, a mais pesquisada por nós. Em toda a LATAM, onde temos presença estratégica, são mais de 1,5 mil ensaios ativos. O câncer tem maiores chances de reversão se diagnosticado precocemente. Previna-se! - Según la OMS, alrededor de 10 millones de personas mueren cada año a causa del cáncer. Para evitar que esta situación empeore, es necesario adoptar rápidamente medidas en todo el mundo. Así, desde el año 2000, la Unión Internacional para el Control del Cáncer (UICC) impulsa una campaña anual para concienciar sobre la prevención y la urgente necesidad de buscar nuevas soluciones en este frente. Como CRO con amplia expertise en oncología, contribuimos activamente a esta búsqueda: el 15% de nuestros estudios se centran en esta área terapéutica, la más investigada por nosotros. En toda LATAM, donde tenemos presencia estratégica, hay más de 1.500 ensayos activos. El cáncer tiene mayores posibilidades de revertirse si se diagnostica a tiempo. ¡Prevenirte! #oncology #healthcareinnovation #oncologia

❓ Are you a patient, healthcare professional, researcher or otherwise affiliated with lobular breast cancer (ILC)? 💡 15 October 2024 is the first Lobular Breast Cancer Global Awareness Day. On this very day, UMC Utrecht, Erasmus MC, Antoni van Leeuwenhoek and Maastricht UMC+ will organize an afternoon symposium to create more awareness among patients, healthcare professionals and researchers about this special type of breast cancer. Experts from various disciplines and institutes, such as Patrick Derksen, Sabine Linn, Paul Van Diest, Thiemo van Nijnatten and patient advocate Rian T., will provide you with the latest insights on research, treatments and more. 🗓 When? 15 October 2024, 13.00-18.00. 🏥 Where? Auditorium Princess Máxima Center, Utrecht Science Park. 🖋 Would you like to register and/or know more about the program: go to https://lnkd.in/eP6sJUSx --- 💝 Quick facts about ILC: 💡Approximately 15% of all breast cancers are invasive lobular carcinoma. 💡Lobular tumor cells develop independently from each other and are often spread within the breast tissue. 💡ILC is harder to detect with mammography or ultrasound, especially in women with dense breasts. MRI is recommended. 💡Most ILC is treated with endocrine (anti-hormone) treatment. European Lobular Breast Cancer Consortium (ELBCC/COST Lobsterpot) | BVN - Borstkankervereniging Nederland | KWF Kankerbestrijding | COST Association - European Cooperation in Science and Technology #cancerresearch #breastcancer #ILC

En una reciente investigación publicada en BMC Cancer, titulada "Inflammatory biomarkers and risk of breast cancer among young women in Latin America: a case-control study," exploramos la relación entre biomarcadores inflamatorios y el riesgo de cáncer de mama en mujeres premenopáusicas de América Latina. Descubrimos que los niveles elevados de IL-6 y TNF-α están asociados con un mayor riesgo de cáncer de mama, especialmente en tumores grandes. Estos hallazgos subrayan la importancia de la inflamación crónica en el desarrollo del cáncer de mama y la necesidad de estudios prospectivos adicionales para confirmar estos resultados y guiar estrategias de prevención y tratamiento en la región. DOI: https://lnkd.in/eqWKz4rC

SNOMED International y la Union for International Cancer Control (UICC) han firmado un acuerdo de colaboración que permitirá la integración de la Clasificación tumoral, ganglionar y metátasis de los tumores malignos (TNM) en SNOMED CT. La Clasificación TNM, que gestiona y publica la UICC, es un estándar reconocido mundialmente para clasificar la extensión y propagación del cáncer. #SNOMEDCT es una terminología clínica integral y multilingüe creada para que la utilicen profesionales de la salud para facilitar el intercambio, el apoyo a las decisiones y el análisis, además de respaldar el intercambio de información sanitaria de forma segura y eficaz.  La Clasificación TNM se utiliza ampliamente en los países miembros de SNOMED International y es recomendada por los Grupos Clínicos de Referencia relevantes de la organización.  Las dos organizaciones garantizarán que los valores de clasificación de la UICC estén representados de una manera que permita a los usuarios identificar sin ambigüedades el contenido de la clasificación de la UICC.   El foco inicial de este esfuerzo será la octava edición de la Clasificación TNM de la UICC; el acuerdo, sin embargo, incluye la incorporación de contenidos relevantes de la novena edición cuando esté disponible. Además, el grupo se asegurará de que los cambios en curso en los valores de estadificación de SNOMED CT y UICC se reflejen en la integración.

Colorectal cancer remains one of Europe’s most pressing health challenges, but together, we can make a difference. As part of our commitment to improving outcomes for high-risk colon cancer patients, the SAGITTARIUS project is proud to highlight the importance of initiatives like the 5th DiCE CRC Screening Summit. Created by Digestive Cancers Europe, a SAGITTARIUS Consortium Partner. This pivotal event is dedicated to enhancing colorectal cancer screening and achieving 90% coverage by 2025. 📅 When: 5 December, 9:00 AM CET 📍 Where: Online Join experts, healthcare professionals, and policymakers to discuss key strategies for: ✅ Expanding access to screening programs ✅ Personalising screening approaches ✅ Mobilising communities for early detection 🎯 Together, we can build a future where early detection and equitable care save lives. 🔗 Register here: https://lnkd.in/eD6wfNbs #SAGITTARIUSProject #5thCRCSummit #ColorectalCancer #CancerScreening #EarlyDetection #CancerAwareness Digestive Cancers Europe Erasmus MC University of Latvia (Latvijas Universitāte) European Commission A.O.U. Città della Salute e della Scienza di Torino Privatklinik Confraternität | PremiQaMed Group The University of Edinburgh IARC - International Agency for Research on Cancer / World Health Organization University of Central Lancashire Bowel Cancer UK Amsterdam UMC